Develops drugs for diabetes and heart disease.
May 2026Revenue $194K/yrExpenses $7.90M/yr
No trendCash runway ≈ 6 months from May 2026
Figures by year
When will Lexaria Bioscience be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to May 2026, revenue was $194K and expenses $7.90M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Aug 2025 | $706K | $12.6M | −$11.9M |
| Aug 2024 | $464K | $6.22M | −$5.75M |
| Aug 2023 | $226K | $6.76M | −$6.53M |
| Aug 2022 | $255K | $6.87M | −$6.62M |
| Aug 2021 | $723K | $6.41M | −$5.69M |
| Aug 2016 | $40.7K | $1.32M | −$1.28M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.